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Introduction
Treatment of viral infections by biological methods 
could be better than chemical medicines due to its wide 
availability and fewer side effects. The biological activity 
of some synthetic peptides includes antifungal, antibacte-
rial, anti-parasitic, antiviral and antitumor activities 1,2. 
Hepatitis C virus (HCV) represents one of the main causes 
of chronic liver diseases leading to hepatic steatosis, fibro-
sis, cirrhosis and hepatocellular carcinoma. There is no 
vaccine available to prevent HCV infection due to the high 
mutation rate during replication among different geno-
types. HCV standard of care until relatively recently was 
a combination of pegylated interferon (peg/IFN) and riba-
virin, and it was only efficient in half of treated patients, 
with many adverse effects. For instance, in patients with 
malignant midgut carcinoid tumors treated with rhIFN-
α2a, 41% developed anti- IFN-α antibodies and 32–42% 
in patients with metastatic renal cell carcinoma. More-
over, it was reported that PEG-IFN-α preparations with 
longer half-life are immunogenic when given to HCV pa-
tients previously receiving conventional IFN-α therapy3. 
However, new interferon-free combinations of direct act-
ing antivirals (DAAs) have revolutionized HCV treatment 
with better response and fewer side effects. Treatment of 
HCV has rapidly progressed with the DAAs development 
targeting genome replication and/or polyprotein process-
ing. DAAs target virally encoded enzymes through a 
poorly defined mode of action. While the success of these 
therapies has been encouraging to date, the long-term re-
sponse and potential for viral resistance remain to be 
seen4 . Several HCV cell culture systems as sub genomic 
replicons, retroviral HCV pseudo particles (HCVpp) and 
the JFH1-based infection system have exposed more in-
formation about the molecular mechanisms involved in 
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A B S T R A C T
The emergence and distribution of Hepatitis C virus (HCV) infection is still considered as an unsolved problem. Due 
to side effects, many synthetic drugs have been avoided and replaced by new biologically derived ones. Aim of this study 
was to use Pseudomonas oleovorans’ extract as HCV viral replication inhibition agent in cell culture system. Several fac-
tors were studied and the optimum growth conditions were selected for maximum production of antiviral substance. 
Pseudomonas oleovorans’ extract was fractionated using different concentrations of chloroform: methanol on silica gel 
columns. Analysis of potent fraction by GC/MS showed tetradecanoic and hexadecanoic acid methyl esters. The selected 
fraction was tested against HCV in vitro using two different protocols: viral attachment entry inhibition (Pre-incubation) 
and viral replication inhibition (Post infection). 0.1 µg / ml of the selected antiviral fraction resulted in inhibition of viral 
replication in Huh 7.5 cells. However, higher concentration of 100 µg / ml did not cause any viral inhibition. The se-
lected bacterial fraction containing tetradecanoic acid and hexadecanoic acid methyl esters could be used as a promising 
candidate to inhibit viral HCV entry and replication of HCV. 
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HCV replic` ation5. Infectious cell culture systems recap 
the entire viral life cycle allowing the studying of the effect 
of all DAAs and HTAs (Host targeting agents). Working 
with primary cells and polarized cells has recently en-
hanced which may help to address some limitations of the 
previously established cell lines 6. Bovine virus diarrhea 
virus (BVDV) is a culture model virus for screening com-
pounds with anti-HCV neutralizing activity due to the 
close relation between the two viruses in sharing signifi-
cant degree of local protein homology and a common rep-
lication strategy 7.
HCV infection as a major cause of chronic liver disease 
extends the need for HCV effective prophylactic vaccine 
globally. Research is extended in using HCV cell culture 
system to identify the essential host factors to complete the 
life cycle of HCV and to identify the mechanisms of various 
interactions between HCV and the infected host. A novel 
production system for vaccine against HCV was established 
using Vero cells 8. The presence of natural antiviral agents 
against HCV has been developed during the last few years. 
Aqueous enzymatic extracts of edible mushroom, Agaricus-
bisporus (AbAEE), have been studied as a key source of 
biological active compounds against HCV proteases 9. 
Grape seed extract (GSE) containing more amounts of 
ﬂavonoids exerted inhibitory effects on HCV replication 
without causing host cellular toxicity10. Soraphen A (SorA) 
is a myxobacterial metabolite with a very potent anti-HCV 
activity11. Echinocystic acid, an oleanane-type triterpene, 
displayed substantial inhibitory activity on HCV entry 12. 
Also, a lipophilic long-chain compound derived from micro-
bial metabolites, an inhibitor of sphingolipid biosynthesis, 
was shown to inhibit HCV replication13. 
In this study, microbial extract derived from Pseudo-
monas oleovorans was used as a potentially inhibitory 
agent of HCV viral replication in cell culture system. The 
fractions were extracted with different concentrations of 
chloroform: methanol on silica gel columns by column 
chromatography. The selected fraction was tested against 
HCV in vitro with two different protocols, to assess inhibi-
tion of viral attachment and entry (Pre-incubation) and 
viral replication (Post infection), respectively
Materials and Methods
Purification and testing of antiviral substance from 
the culture supernatant of Pseudomonas oleovorans was 
carried out in our previous study by extraction with ethyl 
acetate. The ethyl acetate crude extract was fractionated 
by methanol (90%) and n-hexane. The methanol fraction 
was further fractionated to detect and identify the potent 
antiviral compound against BVDV14. 
Gas Chromatography/ Mass Spectrometry 
analyses
Agilent 6890 gas chromatography equipped with an 
agilent mass spectrometric detector with a direct capillary 
interface and fused silica capillary column PAS-ms 
(30m×0.25mmI.D.×0.25um film thickness) was used as 
described earlier14. Helium was used as carrier gas at ap-
proximately 1ml/min pulsed split less mode to inject sam-
ples. The solvent delay was 3 min and the injection size 
was 1.0 µl. The mass spectrophotometric detector was 
operated in electron impact ionization mode an ioning en-
ergy of 70e.v. scanning from m/z 50 to 550. The ion source 
temperature was 250°C and the quadruple temperature 
was 150°C. The electron multiplier voltage (EM voltage) 
was maintained 1550 v above auto tune. The instrument 
was manually tuned using perfluorotributyl amine (PFT-
BA). The GC temperature program started at 60°C then 
was elevated to 280°C at the rate of 8°C/ min and15 min 
holding at 280°C, the injector temperature was set at 
280°C. Wiley mass spectral data base was used in the 
identification of the separated peaks 14.
Establishment of cell culture system infected 
with HCV
Huh7, a well differentiated human hepatocellular car-
cinoma cell line modified to produce a more efficient 
Huh7.5 cell line was a generous gift from Charles Rice 
(The Rockefeller University, USA) obtained under Mate-
rial Transfer Agreement (MTA# 642 to Dr. Mostafa K. El 
Awady 2007). HCV infection experiments and assessment 
of viral replication were done on Huh7.5 cells. HCV posi-
tive serum was collected from HCV infected patient exam-
ined at the Medical Unit at the National Research Centre, 
Cairo, Egypt. The diagnosis of this patient was based on 
physical examination and serological testing, for the pres-
ence of anti-HCV-antibodies in the serum, using a recom-
binant HCV antigen based test (Axium HCV Rapid test, 
Florida, U.S.A.). The HCV infection was confirmed by 
reverse transcription-polymerase chain reaction (RT-PCR) 
as mentioned in our previous studies 15, 16.
Huh7.5 cells were cultured and infected with HCV 
particles according to protocols described by Seipp et 
al.,17 and Song et al.,18. Successful viral infection in 
Huh7.5 cells throughout the culture duration was con-
firmed by Reverse Transcription Polymerase Chain Re-
action (RT-PCR) amplification of HCV RNA at the tran-
scriptional level. Retro-transcription was performed in 25 µl 
reaction mixture containing 3 µl (~400 ng) of the extracted 
RNA, a final concentration of 0.2 mM from each dNTP (MBI 
Fermentas; Germany) and 50 pmol of primers 1CH or 2CH for 
plus or minus strands, respectively and the mixture was preheat-
ed at 92oC for 30 sec then chilled on ice. The sequence of the used 
primers was as following: 1CH: 5՜-GGTGCACGGTCTAC-
GAGACCTC-3՜and 2CH: 5՜-AACTACTGTCTTCACG-
CAGAA-3՜.A total of 40U RNas in (Clontech; U.S.A.), 
20U of reverse transcriptase (RT) isolated from Avian 
Myeloblastosis Virus and 2.5 µl 10X enzyme buffer (AMV 
RT; Q-BIO gene, Germany) were added to the mixture, 
the reaction was incubated in the thermal cycler (T1; 
Whatman Biometra, Goettingen, Germany) at 42oC for 
60 min, then the RT was inactivated and double strand-
ed cDNA was denatured at 95oC for 10 min and chilled 
on ice to keep the DNA strands apart. The amplification 
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of the highly conserved 5՜-non-coding region (NCR) se-
quences was done in 2 rounds of PCR (nested PCR) using 
2 different pairs of primers, one pair in each PCR round. 
The sequence of the primer pair used in the first round 
was: Forward (2CH): sequence was mentioned above and 
the Reverse (P2):5՜-TGCTCATGGTGCACGGTCTA-3՜.
The sequence of the primer pair used in the second round 
was: Forward (F2):5՜-GTGCAGCCTCCAGGACCC-3՜ 
and the reverse (1TS): 5՜-GCGACCCAACACTACTCG-
GCT-3՜.Both reactions were carried out at 50 µl volume 
and the mixture contained 0.2 mM from each dNTP, 5 
µl of each primer, 5µl (10X) reaction buffer containing 
1.5 mM MgCl2, 10 µl cDNA, 2U Taq DNA polymerase 
(FinnzymesOy; Espoo, Finland). Amplification was car-
ried out for 36 cycles each included: Denaturation at 94oC 
for 1min, annealing at 55oC for 1min and extension at 
72oC for 1min.The last cycle was attached to a final ex-
tension step at 72oC for 10 min. Amplification products 
were analyzed by agarose gel electrophoresis using 1.5% 
agarose gel in TBE buffer (0.045M Tris-borate, 0.001M 
EDTA, pH 8.0, as reported by El Abd et al., 19 
Cytotoxicity assay
The extracted fraction of Pseudomonas oleovorans 
was examined at concentrations of 1mg/ml, 100 µg/ml 
and 10 µg/ml as reported in our previous study14. Con-
centrations from the selected fraction used in both pro-
tocols were determined by cytotoxicity assay which was 
discussed before in our previous study using different 
concentrations in comparisons with non-treated cells 
monolayers. Huh7.5 cells were observed for any physical 
signs of toxicity, e.g. partial or complete loss of mono-
layer, rounding, shrinkage, or cell granulation. Accord-
ingly, 1 mg/ml concentration was considered as toxic 
concentration and excluded from further experiments.100 
µg / ml and 0.1 µg / ml concentrations of the selected frac-
tion were used in further experiments.
Evaluation of the antiviral activity of the se-
lected bacterial fraction using viral attachment 
entry inhibition assay (Pre-incubation) (Tabll et 
al.,15 and Yasuhara-Bell et al.,20)
In order to study the effect of the selected bacterial 
fraction from Pseudomonas oleovorans extract on HCV 
infected cells, different concentrations of the selected 
fraction were pre-incubated with HCV serum sample of 
viral load 1.136.648 IU/ml prior to application to Huh7.5 
cells. HCV binding to target cells was detected by nested 
RT- PCR. Briefly, in a 1.5 ml tube, HCV infectious serum 
sample was added to dilutions of the selected fraction 
concentrations 100 µg / ml, 0.1 µg / ml in a final volume 
of 1 ml FCS-free DMEM. Infectious and healthy (HCV 
negative) sera diluted 1:50 in 1ml FCS-free DMEM were 
included as positive and negative controls, respectively. 
All tubes were incubated at 37°C for three hours.
Huh7.5 cells (200,000 cells / well) were grown to 
semi-confluence in DMEM supplied with 10% FCS, 1% 
Penicillin-Streptomycin and 0.1% fungizone in 6 well 
plates for 48 h. After media were removed, cells were 
washed with FCS-free medium twice and inoculated 
with 1ml of the previously incubated sera-fraction mix. 
For each assay, a negative control consisted of two wells 
supplied with DMEM without sera inoculation. After 90 
minutes at 37oC in 5% CO2, 1ml DMEM containing 10% 
FCS was added to each well. On the second day, media 
were aspirated and to get rid of any remaining sera-frac-
tion mix cells were washed three times with PBS, re-
placed with fresh medium DMEM without FCS and cells 
were further incubated for 24 hrs at 37°C. On the third 
day, media were aspirated and 500 µl of solution D was 
added to each well and left for 5 min or untill the cells 
were completely lysed by the solution and then the cell 
lysate was transferred to a 1.5 ml tube. RNA extraction 
was performed from the cell lysate using acid guanidin-
ium-phenol-chloroform method, then HCV RNA detection 
was performed qualitatively by nested RT-PCR and the 
amplicons were visiualized using agarose gel electropho-
resis as reported in our previous study 21.
Evaluation of the antiviral activity of the selected 
bacterial fraction using viral replication inhibi-
tion assay (Post infection)
Huh7.5 cells (200,000 cells / well) were grown to 
semi-confluence for 48 h in 5 % CO2 incubator. The media 
were aspirated, then cells were washed twice with FCS-
free medium and inoculated with 200 µl HCV sera dilut-
ed with FCS-free DMEM and after 90 minutes of icuba-
tion, 1.8 ml DMEM containing 10% FCS was added to 
each well. Two wells were left without sera inoculation 
(supplied just with DMEM) to serve as negative controls. 
The plates were incubated for 24 h. After incubation me-
dia were aspirated and cells were washed three times 
with PBS to get rid of any remaining viral particles. 
Then 500 µl of the previously prepared dilutions of the 
selected fraction concentrations 100 µg / ml, 0.1 µg / ml 
in a final volume of 1ml FCS-free DMEM were added. 
Plates were incubated at 37oC in 5% CO2. On the next 
day, media were aspirated and 500 µl of solution D was 
added to each well and RNA extraction was performed 
from the cell lysate using acid guanidinium-phenol-chlo-
roform method then HCV RNA detection was performed 
qualitatively by nested RT-PCR and the amplicons were 
visiualized using agarose gel electrophoresis 21.
Results
The GC/MS analysis of the fraction with antiviral 
activity against BVDV revealed the presence of satu-
rated fatty acids methyl esters (presence of tetradeca-
noic acid and hexadecanoic acid methyl esters) as shown 
in figure 1.nAbundance of Hexadecanoic acid methyl 
ester C17H34O2at retention time 18.97 min. and Tetra-
decanoic acid 12-methylester C15H30O2 at 17.33 min.
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The nested RT-PCR products (174 bp) were visualized 
on 2% agarose gels. As shown in figures 2 and 3, Pseudo-
monas oleovorans extract with the concentration of 100 
µg/ml cannot prevent viral attachment inhibition (pre-
infection) or HCV viral replication inhibition (post infec-
tion). While the extracted fraction of Pseudomonas oleo-
vorans with the concentration 0.1µg/ml inhibited viral 
entry and RNA replication of hepatitis C virus in cell cul-
ture as shown in figures 2 and 3.
Discussion
In the present study, evaluation of the selected bacteri-
al fraction for antiviral activity against HCV has been de-
tected using both inhibition viral entry (pre-infection) and 
RNA replication inhibition assay (post infection). Results 
Fig. 1. GC/MS analysis of fraction with the antiviral activity. 
Abundance of Hexadecanoic acid methyl ester C17H34O2at 
retention time 18.97 min. and Tetradecanoic acid 12-methyles-
ter C15H30O2 at 17.33 min.both are important as significant 
compounds with antiviral activity.
Fig. 2. Agarose gel electrophoresis of nested RT-PCR products of 
HCV using viral attachment entry inhibition assay (Pre-incu-
bation). M is molecular weight standard DNA marker (100 base 
pair; JenaBioscience, Germany). Lane 1 normal non infected 
Huh7.5 cells (negative control). Lanes 2 and 3: infected Huh7.5 
cells (positive control). Lane 4: Positive serum. Lane 5: infection 
of cells with the patients' serum previously incubated with 
concentration of 0.1 µg / ml of the selected fraction. Lane 6: 
infection of cells with the patients' serum previously incubated 
with concentration of 100 µg/ml of the selected fraction. 
Fig. 3. Agarose gel electrophoresis of nested RT-PCR products of 
HCV using viral replication inhibition assay (Post infection).M 
is molecular weight standard DNA marker (100 base pair; 
JenaBioscience, Germany). Lane 1: infected cells with the 
patients' serum (positive control). Lanes 2, 3 and 4: normal non 
infected Huh7.5 cells (negative control).Lane 5: infection of cells 
with the patients' serum previously incubated with concentra-
tion of 0.1 µg/ml of the selected fraction. Lane 6: infection of 
cells with patients' serum previously incubated with concentra-
tion of 100 µg / ml of the selected fraction. Lanes 7 and 8: 
positive and negative sera.
of the first inhibition assay indicated that, 100 µg/ml from 
the selected fraction did not affect viral attachment, how-
ever, the use of 0.1 µg/ml of the fraction led to full inhibition 
of the virus. This indicated the probability of using this 
fraction to block both viral attachment and entry to the host 
cell. As, it was able to neutralize the virus infectivity 
through binding to and/or blocking the virus itself or 
through blocking cellular receptors which are responsible 
for the entry of the virus in the host cell as shown by RT-
PCR for HCV RNA. 
The second method for determination of antiviral activ-
ity against HCV was through the viral replication inhibi-
tion assay. In this method cells were infected with HCV 
RNA positive serum before adding the selected fraction of 
the bacterial extract. Treating the infected HCV cells with 
two different concentrations of the selected fraction led to 
inhibition of viral replication using lower concentration 
rather than the high one. When the fraction was added to 
the infected cells the virus lost its ability to re-infect new 
host cells. It is not yet known if this is due to the inhibitory 
effect of the fraction of the bacterial extract against the 
active molecules of the virus or due to the decreased infec-
tivity of the virus released substances in to the media. The 
same explanation was suggested for the antiviral activity 
of extracted marine microorganisms against herpes sim-
plex virus (HSV-1) and vesicular stomatitis virus (VSV) 20. 
Several polyunsaturated fatty acids (PUFAs) as eicos-
apentaenoic acid (EPA), arachidonic acid (AA) and docosa-
hexaenoic acid (DHA) showed anti-HCV activities using 
HCV sub genomic RNA replicon system. The mechanism 
of action PUFAs in the inhibition of HCV replication was 
not clear 22. Consistent with the importance of the fatty-ac-
id-biosynthetic pathway in HCV RNA replication, saturat-
ed and monounsaturated fatty acids can improve RNA 
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replication of HCV. HCV replication has been demonstrated 
to occur in an HCV-induced “membranous web” consisting 
of modified lipid-containing intracellular vesicles; it is pos-
sible to suggest that fatty acids are required for the right 
folding of this structure that is required for HCV RNA rep-
lication 23. Inhibition of fatty acid synthase (FASN) led to 
decrease in the replication of sub genomic HCV replicons 
as well as HCV virion production. Although the underlying 
mechanisms are not yet completely understood, these stud-
ies imply that FASN was crucial for the virus replication 24. 
This contributed to studying the use of fatty acids for inhi-
bition of HCV as a source for new drug development. Viral 
resistance has evolved with the development of several an-
ti-HCV drugs, thus new drugs inhibiting the host factor 
that contributes to HCV replication in arrangement with 
the era of the DAAs may solve this problem. The main ele-
ment in the efficacy of viral replication is well-defined 
through an enzyme for long-chain mono-unsaturated fatty 
acid (LCMUFA) synthesis called stearoyl-CoA desaturase 
(SCD). SCD-1 inhibitors could be used together with inter-
feron-alpha as multi-drug anti-viral agents against HCV 
25. Since the advent of (DAA) agents, chronic HCV treat-
ment has evolved at a rapid pace. In contrast to prior regi-
men involving ribavirin and pegylated interferon, these 
newer agents are highly effective, well-tolerated, have 
shorter course of therapy and are safer essentially in all 
HCV patients including those with advanced liver disease 
and following liver transplantation 26. 
A similar study on Pseudomonas oleovorans strain 
KBPF-004 (developmental code KNF2016) showed antivi-
ral activity against mechanical transmission of tobamo 
viruses. Antiviral activity was also evaluated in seed trans-
mission of two tobamo viruses, Pepper mild mottle virus 
(PMMoV) and Cucumber green mottle mosaic virus (CGM-
MV), by treatment of seeds collected from infected pepper 
and watermelon, respectively. Supernatant of P. oleovorans 
strain KBPF-004 remodeled aggregation of PMMoV 126 
kDa protein and subcellular localization of movement pro-
tein in Nicotiana benthamiana, diminishing aggregation 
of the 126 kDa protein and essentially abolishing associa-
tion of the movement protein with the microtubule network. 
In leaves agro infiltrated with constructs expressing the 
coat protein (CP) of either PMMOV or CGMMV, less full-
size CP was detected in the presence of supernatant of P. 
oleovorans strain KBPF-004. These changes may contrib-
ute to the antiviral effects of P. oleovorans strain KBPF-
004 27. Further study could use a new strategy based on 
substitution of human serum infected Huh7.5 cells with 
HCVcc infection system, and then apply treatment with 
purified compounds extracted from bacterial isolates. This 
may contribute in part to the inference with HCV replicat-
ing system. In addition, preclinical studies in small exper-
imental animals to study the cytotoxicity of bacterial ex-
tracts (liver and kidney functions, hematological and 
pathological changes) should be carried out. This might 
give new venues to be applied for the treatment of HCV.
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EKSTRAHIRANA FRAKCIJA PSEUDOMONAS OLEOVORANS MOŽE INHIBIRATI ULAZAK VIRUSA I 
REPLIKACIJU RNA VIRUSA HEPATITISA C U KULTURI STANICA
S A Ž E T A K
Pojava i distribucija infekcije virusom hepatitisa C (HCV) i dalje se smatra neriješenim problemom. Zbog nuspojava, 
mnogi sintetički lijekovi se izbjegavaju i zamijenjuju novim biološki dobivenim lijekovima. Cilj ovog istraživanja bio je 
koristiti ekstrakt Pseudomonas oleovorans kao sredstvo za inhibiciju replikacije HCV virusa u sustavu stanične kulture. 
Proučavano je nekoliko čimbenika i odabrani su optimalni uvjeti rasta za maksimalnu proizvodnju antivirusne tvari. 
Ekstrakt Pseudomonas oleovorans je frakcioniran korištenjem različitih koncentracija kloroform: metanol na stupcima 
silikagela. Analiza jake frakcije pomoću GC / MS pokazala je metil estere tetradekanoične i heksadekanske kiseline. 
Odabrana frakcija je testirana na HCV in vitro pomoću dva različita protokola: inhibicija ulaska virusa (pre-inkubacija) 
i inhibicija replikacije virusa (Post infekcija). 0,1 ug / ml odabrane antivirusne frakcije rezultiralo je inhibicijom virusne 
replikacije u Huh 7,5 stanicama. Međutim, veća koncentracija od 100 ug / ml nije uzrokovala nikakvu virusnu inhibic-
iju. Odabrana bakterijska frakcija koja sadrži tetradekanoičnu kiselinu i metil estere heksadekanske kiseline može se 
smatrati kandidatom za inhibiciju virusnog HCV ulaska i replikacije HCV.
